⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14686375 | 0.77 | — | — | |
| SCHEMBL1992168 | 0.77 | — | — | |
| SCHEMBL27882777 | 0.77 | — | — | |
| SCHEMBL7332906 | 0.76 | — | — | |
| SCHEMBL4697090 | 0.75 | — | — | |
| Water SCHEMBL8419706 | 0.75 | ALDH1A1 (0.38) | — | |
| SCHEMBL163984 | 0.74 | — | — | |
| SCHEMBL1722804 | 0.73 | — | — | |
| SCHEMBL10422131 | 0.71 | TRPA1 (0.39) | — | |
| SCHEMBL6139537 | 0.71 | ALDH1A1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277190-A1 | PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR | ABBVIE INC. | 2012-11-01 | — | — | US | disclosed |
| US-8232309-B2 | Prodrugs of compounds that inhibit TRPV1 receptor | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| EP-1957464-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR | Abbott Laboratories (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007050732-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR | ABBOTT LABORATORIES (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070099954-A1 | Prodrugs of compounds that inhibit TRPV1 receptor | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| US-6784184-B2 | FOR THERAPY OF RAS- ONCOGENE-DEPENDENT TUMORS, SUCH AS CANCERS OF PANCREAS, COLON, BLADDER, AND THYROID; USEFUL FOR CONTROLLING METASTASIS, SUPPRESSING ANGIOGENESIS, INDUCING APOPTOSIS, AND RAS-ASSOCIATED PROLIFERATIVE DISEASES | WYETH HOLDINGS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-6605628-B1 | Treatment of ras oncogene-dependent tumors; controlling metastasis, suppressing angiogenesis, inducing apoptosis | WYETH HOLDINGS CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-20030149063-A1 | 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase | AMERICAN CYANAMID COMPANY | 2003-08-07 | — | — | US | disclosed |
| US-20030144301-A1 | Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase | AMERICAN CYANAMID COMPANY (US) | 2003-07-31 | — | — | US | disclosed |
| WO-2003018135-A1 | METHOD OF USING 5-(ARYLSULFONYL)-,5-(ARYLSULFINYL), AND 5-(ARYLSULFANYL)-THIAZOLIDINE-2,4-DIONES FOR INHIBITION OF FARNESYL-PROTEIN TRANSFERASE | WYETH HOLDINGS CORPORATION (US) | 2003-03-06 | — | — | WO | disclosed |